Chinese AI medical enterprise Yidu Technology has launched the clinical evidence-based intelligent agent "Yidu Zhixun" mini program, which focuses on the practical needs of doctors in clinical diagnosis and research work, aiming to provide clinical decision support for doctors. The related functions have been opened for use in the industry. Previously, "Yi Du Zhi Xun" has completed clinical in-depth verification in medical institutions such as Sun Yat sen University Cancer Center, covering 15 core tumor types such as lung cancer, breast cancer, liver cancer, colorectal cancer, etc. Yidu Technology stated that in the above clinical validation, the recommended treatment plan for this product has a high degree of fit with the decisions of clinical doctors. Before the product was launched, "Yidu Zhixun" conducted a one week internal test, with more than 6000 medical industry professionals participating. The platform has collected nearly 2000 valid user feedback. Clinical doctors have stated that this product has practicality in areas such as guideline knowledge inquiry, treatment plan generation, drug interaction verification, tumor staging evaluation, clinical trial retrieval, and tracking of medical frontiers. It can improve the efficiency of clinical information retrieval and provide corresponding support for evidence-based decision-making. From the perspective of product content construction, "Yidu Zhixun" is based on an evidence-based evaluation system, screening and integrating medical resources, including over 30000 authoritative guidelines and over 5 million high-quality scientific research achievements. At the same time, the product has also collaborated with institutions such as the People's Health Publishing House to build a disease and drug knowledge base, ensuring the professionalism of the content through clinical expert review. To help doctors obtain cutting-edge medical evidence in a timely manner, this product continuously tracks the latest research results of top international medical journals such as The New England Journal of Medicine, The Lancet, and The Journal of the American Medical Association, creating a dynamic knowledge base. It is reported that the APP version of "Yidu Zhixun" will also be launched in the near future, and more functional modules will be launched to provide users with a more comprehensive user experience. (New Society)